All articles tagged with #dapagliflozin
A clinical trial in China found that the diabetes drug dapagliflozin improves conditions related to liver disease, specifically metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, with significant improvements observed compared to placebo, though further research is needed for broader validation.
Research indicates that the diabetes drugs canagliflozin and dapagliflozin, which help the body expel excess fluid, can significantly reduce the risk of kidney stones and gout in patients. These SGLT-2 drugs, already known to lower the risk of early death and hospitalization in diabetics, are now suggested as a primary treatment option. The study from the University of British Columbia followed 20,000 diabetics and found a 30% reduction in the likelihood of developing these conditions, highlighting the potential of these drugs to improve the quality of life for diabetics.
The DAPA-MI trial, which investigated the use of dapagliflozin in acute myocardial infarction (MI) patients, showed significant improvements in cardiometabolic outcomes but did not have an impact on cardiovascular death or heart failure hospitalizations, the trial's original primary endpoint. The trial had to switch to a hierarchical win-ratio analysis due to low event rates, combining several clinical endpoints. The results suggest that dapagliflozin may have benefits in reducing the risk of developing heart failure, diabetes, hypertension, and other cardiometabolic conditions in acute MI patients. However, some experts remain skeptical about the implementation of dapagliflozin in this patient population, citing the modest absolute reductions in new diabetes diagnoses and weight loss.